Matches in Wikidata for { <http://www.wikidata.org/entity/Q99585757> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q99585757 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q99585757 description "scientific article published on 20 September 2020" @default.
- Q99585757 description "wetenschappelijk artikel" @default.
- Q99585757 description "наукова стаття, опублікована 20 вересня 2020" @default.
- Q99585757 name "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-author" @default.
- Q99585757 name "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-author" @default.
- Q99585757 type Item @default.
- Q99585757 label "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-author" @default.
- Q99585757 label "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-author" @default.
- Q99585757 prefLabel "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-author" @default.
- Q99585757 prefLabel "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-author" @default.
- Q99585757 P1433 Q99585757-EB9142B4-233B-4A6A-AB83-F0065BC1A2ED @default.
- Q99585757 P1476 Q99585757-8C02CDAD-29E5-4044-8EEC-4C03B751DF1E @default.
- Q99585757 P2093 Q99585757-07B8AC8D-0D71-4AF8-96E1-17522CEDDA43 @default.
- Q99585757 P2093 Q99585757-150BC230-AF85-4665-ADF6-0426C53005EE @default.
- Q99585757 P2093 Q99585757-2AB7715D-3443-425D-BB34-9D582B3CF441 @default.
- Q99585757 P2093 Q99585757-3A410EFA-1567-438C-978F-6EB73A8A5C83 @default.
- Q99585757 P2093 Q99585757-3E365C88-BAE4-406C-920A-1EDC038826FF @default.
- Q99585757 P2093 Q99585757-409062A7-36E3-4786-9CE4-BA5704BF5A24 @default.
- Q99585757 P2093 Q99585757-54AD6DB5-854D-434E-B9E7-AE79C151CD7B @default.
- Q99585757 P2093 Q99585757-63C3F60A-D7D7-434F-9243-612617279D8C @default.
- Q99585757 P2093 Q99585757-85F02805-CF2E-4D48-BB82-2167A11DD4F3 @default.
- Q99585757 P2093 Q99585757-8AD44151-4A63-40E5-A018-3B58AEAE5EA8 @default.
- Q99585757 P2093 Q99585757-B58542A2-CD70-4C7B-B025-A34BD26C5ACC @default.
- Q99585757 P2093 Q99585757-BDFB1C07-C716-4468-911F-987CBA2001A7 @default.
- Q99585757 P2093 Q99585757-CE39501A-FBE8-4B97-9555-67233B1B53F9 @default.
- Q99585757 P2093 Q99585757-E00450B2-D485-4038-B82B-5D08F0D9065B @default.
- Q99585757 P2093 Q99585757-FEDE7AA9-C6D3-4350-82CB-5D84BA15D6BD @default.
- Q99585757 P31 Q99585757-43525F0F-CDA4-4245-A50E-8CA925A58169 @default.
- Q99585757 P356 Q99585757-5E83C763-A6AA-4140-A08C-FE574F017F68 @default.
- Q99585757 P50 Q99585757-8E4BFD61-23E0-4353-AC31-CEA70F665234 @default.
- Q99585757 P50 Q99585757-CE59C88B-FF82-4EB5-A858-289C2D35746B @default.
- Q99585757 P50 Q99585757-EC2C0CB8-E9C3-430E-ADBE-09530925F373 @default.
- Q99585757 P577 Q99585757-BF499A93-FDCA-4C5B-9CCA-3E48F0F17973 @default.
- Q99585757 P698 Q99585757-E3C16C8F-9B78-4621-9787-2C91A10D0FCC @default.
- Q99585757 P921 Q99585757-6808E621-FD52-4FA0-BDF0-FD9F95A8044A @default.
- Q99585757 P356 DKAA341 @default.
- Q99585757 P698 32954404 @default.
- Q99585757 P1433 Q6294770 @default.
- Q99585757 P1476 "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response" @default.
- Q99585757 P2093 "Cathia Soulié" @default.
- Q99585757 P2093 "Christine Katlama" @default.
- Q99585757 P2093 "Dominique Costagliola" @default.
- Q99585757 P2093 "Esteban Martinez" @default.
- Q99585757 P2093 "Fanny Cardon" @default.
- Q99585757 P2093 "Gilles Peytavin" @default.
- Q99585757 P2093 "Jacqueline Capeau" @default.
- Q99585757 P2093 "Jacques Reynes" @default.
- Q99585757 P2093 "Lambert Assoumou" @default.
- Q99585757 P2093 "Lydie Béniguel" @default.
- Q99585757 P2093 "Marc-Antoine Valantin" @default.
- Q99585757 P2093 "Olivier Bouchaud" @default.
- Q99585757 P2093 "Sami Kolta" @default.
- Q99585757 P2093 "Severine Gibowski" @default.
- Q99585757 P2093 "Soraya Fellahi" @default.
- Q99585757 P31 Q13442814 @default.
- Q99585757 P356 "10.1093/JAC/DKAA341" @default.
- Q99585757 P50 Q108298727 @default.
- Q99585757 P50 Q111669983 @default.
- Q99585757 P50 Q41564214 @default.
- Q99585757 P577 "2020-09-20T00:00:00Z" @default.
- Q99585757 P698 "32954404" @default.
- Q99585757 P921 Q421552 @default.